Last checked at 31 Mar 2017 09:31
The headline for the Avacta Group announcement released on 31 March 2017 at 7.00am under RNS No 0871B should read: Avacta to Present at Investor Evening Hosted by Turner Pope Investments
The announcement text is unchanged and is reproduced in full below.
31st March 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta to Present at Investor Evening Hosted by Turner Pope Investments
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at an investor evening hosted by Turner Pope Investments (TPI) Ltd. The event will be held on Wednesday 5th April in the City of London EC4 and will commence at 5pm.
To register your interest please contact neill@turnerpope.com or call 020 3621 4120.
ENDS
Notes to Editors
For further information from Avacta Group plc, please contact:
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer
| Tel: +44 (0) 844 414 0452 www.avacta.com |
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane - Corporate Broking
WG Partners David Wilson Nigel Barnes Claes Spang
| Tel: +44 (0) 207 220 0500 www.finncap.com
Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217 www.wgpartners.co.uk
|
Zyme Communications (Trade and Regional Media) Katie Odgaard
FTI Consulting (Financial Media and IR) Simon Conway / Natalie Garland-Collins | Tel: +44 (0)7787 502 947 katie.odgaard@zymecommunications.com
Tel: +44 (0) 203 727 1000 avacta@fticonsulting.com |
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is also commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.